SCHEMBL26635835

SCHEMBL26635835

CCOC(=O)CCC1(C)CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TSHR P16473 3/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
ALDH1A1 P00352 3/20 0.37
ADORA1 P30542 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
HPGD P15428 2/20 0.36
KDM4E B2RXH2 1/20 0.36
GLA P06280 1/20 0.36
RECQL P46063 1/20 0.36
HSD17B10 Q99714 1/20 0.36
EPHX2 P34913 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27086843 0.92 L3MBTL1 (0.39) USP2SMN1; SMN2TSHRLMNAPOLB
SCHEMBL4689282 0.86 USP2 (0.41) USP2SMN1; SMN2TSHRLMNAPOLB
SCHEMBL21644360 0.86 USP2 (0.43) USP2SMN1; SMN2TSHRDDB1CRBN
SCHEMBL18044513 0.86 SMN1; SMN2 (0.43) USP2SMN1; SMN2TSHRLMNAPOLB
SCHEMBL7095094 0.85 GPR4 (0.40) USP2SMN1; SMN2TSHRLMNAPOLB
SCHEMBL26636170 0.85 USP2 (0.40) USP2SMN1; SMN2TSHRLMNAPOLB
SCHEMBL4248884 0.85 ALDH1A1 (0.38) USP2SMN1; SMN2TSHRLMNAPOLB
SCHEMBL7095095 0.84 USP2 (0.39) USP2SMN1; SMN2TSHRLMNAPOLB
SCHEMBL16126090 0.83 USP2 (0.45) USP2SMN1; SMN2TSHRLMNADDB1
SCHEMBL28983610 0.83 SMN1; SMN2 (0.40) USP2SMN1; SMN2TSHRPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4519259-A1 TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS Treeline Biosciences, Inc. (US) 2025-03-12 EP disclosed
US-20240238423-A9 TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS Treeline Biosciences, Inc. 2024-07-18 US disclosed
US-20230390404-A1 TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS TREELINE BIOSCIENCES INC (US) 2023-12-07 US disclosed
WO-2023215482-A1 TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS Treeline Biosciences, Inc. (US) 2023-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240238423-A9 TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS BCL2A1, BCL2L1, BCL3 USP2 950/4885SMN1; SMN2 2604/4885TSHR 4074/4885
US-20230390404-A1 TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS BCL2A1, BCL2L1, BCL3 USP2 950/4885SMN1; SMN2 2604/4885TSHR 4074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.